Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action
Breast cancer is one of the most significant causes of mortality among women and the second most prevalent cancer worldwide. Estrogen receptor (ER)-positive breast cancers are the most common molecular subtype of breast cancer, comprising about 70% of breast carcinoma diagnoses worldwide. Endocrine...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/or.2025.1564642/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|